|
July 26, 2011
BioSignia Board Elects Chairman
BioSignia today announced the election of E. B. Chester as
Chairman of the Board of Directors of BioSignia. He was elected by
unanimous vote of the Directors at its recent quarterly meeting in
Raleigh, NC.
Mr. Chester joined the Board of Directors of
BioSignia in January of 2011 and has had an immediate impact on the
commercialization of BioSignia’s technologies. “I am proud to be the
Chairman of the Board of Directors of an organization that is poised
to become a market leader in several industries. It’s an honor,”
said Chester.
Mr. Chester’s business experience includes
ownership and executive management of privately and publically owned
businesses in Manufacturing, Cable Television, Outdoor Advertising,
Banking, Real Estate Aviation Services and Power sports. Currently
he and his family are one of the larger group owners of
Harley-Davidson dealerships in the United States.
“E. B.
Chester has been a valuable member of our Board of Directors,” said
John A. Williams, President and CEO of BioSignia. “His background in
finance and sales is a tremendous resource and BioSignia is
privileged to have someone with his experience leading our Board.”
Mr. Chester lives in Beaver Creek, Colorado and Paradise Valley,
Arizona. He will become an active member of BioSignia’s leadership.
For more information on BioSignia, please call 888.324.6627 or
email info@biosignia.com.
***
About BioSignia
Headquartered in Cary, N.C., BioSignia is a leading technology
and software company focused
on bringing innovative risk assessment modeling solutions to the preventive healthcare
and life insurance underwriting markets. BioSignia's patented
Technology, Synthesis Analysis, provides the underpinnings of the
healthcare application, Know Your Number® (KYN), and life insurance application, Mortality Assessment Technology® (MAT).
This modeling capability represents a quantum leap forward in both morbidity and mortality risk assessment. BioSignia's R&D
team has continued to advance synthesis modeling, continuously updating it to reflect the ever expanding need for better risk
assessment, as well as effective chronic disease prevention, management, and treatment. For more information about BioSignia, visit:
www.biosignia.com.
|
